展望未来：胰腺癌管理中的生物标志物
Looking to the future: biomarkers in the management of pancreatic adenocarcinoma.
作者信息
Spratlin Jennifer L, Mulder Karen E
机构信息
Department of Oncology, Cross Cancer Institute, School of Cancer, Imaging and Engineering Sciences, Faculty of Medicine and Dentistry, University of Alberta, 11560 University Avenue, Edmonton, Alberta, T6G 1Z2, Canada.
出版信息
Int J Mol Sci. 2011;12(9):5895-907. doi: 10.3390/ijms12095895. Epub 2011 Sep 14.
Abstract
The incidence and mortality of pancreas cancer converge. There has been little advancement in the treatment of pancreas cancer since the acceptance of gemcitabine as the standard therapy. Unfortunately, the efficacy of gemcitabine is dismal. While there is much discussion for the development of biomarkers to help direct therapy in this area, there is little action to move them into clinical practice. Herein, we review potential pancreatic cancer biomarkers and discuss the limitations in their implementation.
摘要
胰腺癌的发病率和死亡率趋于一致。自吉西他滨被接受为标准治疗方法以来，胰腺癌的治疗进展甚微。不幸的是，吉西他滨的疗效不佳。虽然关于开发生物标志物以指导该领域治疗的讨论很多，但将其应用于临床实践的行动却很少。在此，我们综述了潜在的胰腺癌生物标志物，并讨论了其应用中的局限性。
相似文献
1
Looking to the future: biomarkers in the management of pancreatic adenocarcinoma.展望未来：胰腺癌管理中的生物标志物
Int J Mol Sci. 2011;12(9):5895-907. doi: 10.3390/ijms12095895. Epub 2011 Sep 14.
2
The past, present, and future of biomarkers: a need for molecular beacons for the clinical management of pancreatic cancer.生物标志物的过去、现在与未来：胰腺癌临床管理中对分子信标的需求
Adv Surg. 2011;45:301-21. doi: 10.1016/j.yasu.2011.04.002.
3
Solitary cutaneous metastasis on the buttock: a disclosing sign of pancreatic adenocarcinoma.
Clin Exp Dermatol. 2000 May;25(3):201-3. doi: 10.1046/j.1365-2230.2000.00614.x.
4
Prognostic effect of hENT1, dCK and HuR expression by morphological type in periampullary adenocarcinoma, including pancreatic cancer.hENT1、dCK和HuR表达对包括胰腺癌在内的壶腹周围腺癌形态学类型的预后影响。
Acta Oncol. 2016;55(3):286-96. doi: 10.3109/0284186X.2015.1075663. Epub 2015 Sep 11.
5
Gemcitabine and cancer of the pancreas: new preparation. Helpful or not?
Prescrire Int. 1999 Jun;8(41):74-5.
6
Prognostic and predictive markers in pancreatic adenocarcinoma.胰腺腺癌的预后和预测标志物
Dig Liver Dis. 2016 Mar;48(3):223-30. doi: 10.1016/j.dld.2015.11.001. Epub 2015 Nov 14.
7
Subcutaneous metastasis as the first manifestation of a solid-pseudopapillary tumor of the pancreas.
Clin Transl Oncol. 2006 Feb;8(2):136-8. doi: 10.1007/s12094-006-0172-z.
8
The Quest for an Effective Treatment for an Intractable Cancer: Established and Novel Therapies for Pancreatic Adenocarcinoma.探索治疗难治性癌症的有效方法：胰腺癌的现有和新型治疗方法。
Adv Cancer Res. 2015;127:283-306. doi: 10.1016/bs.acr.2015.04.009. Epub 2015 May 21.
9
Biomarkers in pancreatic ductal adenocarcinoma.胰腺导管腺癌的生物标志物。
Clin Transl Oncol. 2017 Dec;19(12):1430-1437. doi: 10.1007/s12094-017-1691-5. Epub 2017 Jun 14.
10
The molecular biology of pancreatic adenocarcinoma: translational challenges and clinical perspectives.胰腺导管腺癌的分子生物学：转化挑战与临床展望。
Signal Transduct Target Ther. 2021 Jul 5;6(1):249. doi: 10.1038/s41392-021-00659-4.
引用本文的文献
1
Relationship Between the Expression of O-Methylguanine-DNA Methyltransferase (MGMT) and p53, and the Clinical Response in Metastatic Pancreatic Adenocarcinoma Treated with FOLFIRINOX.O-甲基鸟嘌呤-DNA甲基转移酶（MGMT）与p53的表达之间的关系，以及接受FOLFIRINOX治疗的转移性胰腺腺癌的临床反应
Clin Drug Investig. 2017 Jul;37(7):669-677. doi: 10.1007/s40261-017-0522-3.
2
Laminin, gamma 2 (LAMC2): a promising new putative pancreatic cancer biomarker identified by proteomic analysis of pancreatic adenocarcinoma tissues.层粘连蛋白γ2（LAMC2）：通过对胰腺腺癌组织的蛋白质组学分析鉴定的一种有前途的新的胰腺癌潜在生物标志物。
Mol Cell Proteomics. 2013 Oct;12(10):2820-32. doi: 10.1074/mcp.M112.023507. Epub 2013 Jun 24.
3
Phase I study of oxaliplatin in combination with gemcitabine, irinotecan, and 5-fluorouracil/leucovorin (G-FLIE) in patients with metastatic solid tumors including adenocarcinoma of the pancreas.奥沙利铂联合吉西他滨、伊立替康及5-氟尿嘧啶/亚叶酸钙（G-FLIE）用于包括胰腺腺癌在内的转移性实体瘤患者的I期研究。
J Gastrointest Cancer. 2013 Jun;44(2):182-9. doi: 10.1007/s12029-012-9466-2.
4
miR-143 inhibits the metastasis of pancreatic cancer and an associated signaling pathway.微小RNA-143抑制胰腺癌转移及相关信号通路。
Tumour Biol. 2012 Dec;33(6):1863-70. doi: 10.1007/s13277-012-0446-8. Epub 2012 Oct 16.
5
The predictive role of p16 deletion, p53 deletion, and polysomy 9 and 17 in pancreatic ductal adenocarcinoma.p16 缺失、p53 缺失以及 9 号和 17 号染色体三体在胰腺导管腺癌中的预测作用。
Pathol Oncol Res. 2013 Jan;19(1):35-40. doi: 10.1007/s12253-012-9555-3. Epub 2012 Jul 11.
本文引用的文献
1
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.FOLFIRINOX 对比吉西他滨治疗转移性胰腺癌。
N Engl J Med. 2011 May 12;364(19):1817-25. doi: 10.1056/NEJMoa1011923.
2
TP53INP1 decreases pancreatic cancer cell migration by regulating SPARC expression.TP53INP1 通过调节 SPARC 的表达抑制胰腺癌迁移。
Oncogene. 2011 Jul 7;30(27):3049-61. doi: 10.1038/onc.2011.25. Epub 2011 Feb 21.
3
A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603).一项曾接受治疗的转移性胰腺腺癌患者中马来酸舒尼替尼的癌症和白血病组 B 期 II 期研究（CALGB 80603）。
Oncologist. 2010;15(12):1310-9. doi: 10.1634/theoncologist.2010-0152. Epub 2010 Dec 10.
4
Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.基于吉西他滨的辅助化疗后胰腺癌中基因表达水平作为预后预测标志物。
Neoplasia. 2010 Oct;12(10):807-17. doi: 10.1593/neo.10458.
5
Hypoxia inducible BHLHB2 is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma.缺氧诱导因子 BHLHB2 是胰腺导管腺癌的一个新的独立预后标志物。
Biochem Biophys Res Commun. 2010 Oct 22;401(3):422-8. doi: 10.1016/j.bbrc.2010.09.070. Epub 2010 Sep 21.
6
Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial.胰腺癌切除术后氟尿嘧啶加亚叶酸辅助化疗与吉西他滨的随机对照试验。
JAMA. 2010 Sep 8;304(10):1073-81. doi: 10.1001/jama.2010.1275.
7
Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium.吉西他滨联合索拉非尼治疗晚期胰腺癌患者：芝加哥大学二期联盟的一项二期临床试验。
Invest New Drugs. 2012 Feb;30(1):382-6. doi: 10.1007/s10637-010-9526-z. Epub 2010 Aug 28.
8
CD10+ pancreatic stellate cells enhance the progression of pancreatic cancer.CD10+ 胰腺星状细胞促进胰腺癌的进展。
Gastroenterology. 2010 Sep;139(3):1041-51, 1051.e1-8. doi: 10.1053/j.gastro.2010.05.084. Epub 2010 Jun 8.
9
Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205.吉西他滨联合西妥昔单抗对比吉西他滨治疗晚期胰腺腺癌的 III 期研究：西南肿瘤协作组指导下的多中心临床试验 S0205。
J Clin Oncol. 2010 Aug 1;28(22):3605-10. doi: 10.1200/JCO.2009.25.7550. Epub 2010 Jul 6.
10
Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).吉西他滨联合贝伐珠单抗对比吉西他滨联合安慰剂治疗晚期胰腺癌患者：癌症和白血病 B 组（CALGB 80303）的 III 期试验。
J Clin Oncol. 2010 Aug 1;28(22):3617-22. doi: 10.1200/JCO.2010.28.1386. Epub 2010 Jul 6.
Zotero 插件